WO2017146514A1 - Composition cosmétique de soin capillaire contenant un mutant de facteur de croissance des fibroblastes 9 hautement stable en tant que substance active - Google Patents

Composition cosmétique de soin capillaire contenant un mutant de facteur de croissance des fibroblastes 9 hautement stable en tant que substance active Download PDF

Info

Publication number
WO2017146514A1
WO2017146514A1 PCT/KR2017/002042 KR2017002042W WO2017146514A1 WO 2017146514 A1 WO2017146514 A1 WO 2017146514A1 KR 2017002042 W KR2017002042 W KR 2017002042W WO 2017146514 A1 WO2017146514 A1 WO 2017146514A1
Authority
WO
WIPO (PCT)
Prior art keywords
growth factor
hair
weight
cosmetic composition
fibroblast growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2017/002042
Other languages
English (en)
Korean (ko)
Inventor
신항철
박연희
오종광
선승택
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PnP Biopharm Co Ltd
Original Assignee
PnP Biopharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PnP Biopharm Co Ltd filed Critical PnP Biopharm Co Ltd
Publication of WO2017146514A1 publication Critical patent/WO2017146514A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Definitions

  • the present invention relates to a hair care cosmetic composition comprising a highly stable fibroblast growth factor-9 variant as an active ingredient. More specifically, the present invention relates to a cosmetic composition capable of promoting hair production and growth, inhibiting hair follicle cell death factors, inhibiting androgen hair loss, and improving blood circulation and feeding nutrients through regeneration and differentiation of hair follicle cells. .
  • Human hair has a growth cycle, the age, the rest period. The cycle is 4-7 years for females and 2-5 years for males, growing 1-1.5 cm per month. Generally, the number of human hair is about 10-120,000 and it is normal to lose 40-100 strands per day. As this normal hair cycle is affected by various causes such as genetic, environmental, and nutritional factors, hair loss progresses. Hair loss directly affects the appearance and thus provides a great concern for modern people, and the stress caused by hair loss is rather aggravating hair loss.
  • Growth factors play an important role in regulating cell growth, proliferation and differentiation. Therefore, there is a system that naturally repairs skin damage, aging, and hair loss caused by internal and external factors such as wounds and surgery, and growth factors play an important role here.
  • various growth factors are generated and maintained at a constant concentration. Growth factors in each tissue are lowered by age or by external factors, and the regeneration and division of cells are weakened, causing wrinkles, decreasing elasticity, and causing hair loss.
  • Hair loss treatments are currently being marketed by pharmaceutical companies based on the US FDA-approved Oral Pinesteride (Propecia) and the external drug Minoxidil.
  • rogaine minoxidil
  • rogaine accounts for about 57.7% of the US market, but it is less effective than expected, and when the drug is discontinued, hair loss resumes, erectile dysfunction, decreased libido, breast enlargement, or birth defects. Growth is limited.
  • various products using herbal-derived extracts have been introduced, but their efficacy and mechanism of activity have not been properly validated.
  • Apoptosis factors (BMP, DKK-1, TGF-beta, IL-1, FGF5, etc.) are stimulated when hair loss-causing factors such as DHT (dihydrotestosterone) or various stresses act on hair-producing hair papilla cells. TNF-alpha) is released. These factors send apoptosis signals to autologous and peripheral cells, causing the protein in the cell to degrade and hair loss to begin. Therefore, in order to suppress hair loss effectively, it is necessary to suppress the production of factors induced and produced by DHT.
  • DHT dihydrotestosterone
  • hair growth requires differentiation of stem cells into papilla cells, activation of papilla cells, and activation of Wnt / beta-catenin, a signaling signal for differentiation.
  • Wnt / beta-catenin a signaling signal for differentiation.
  • Such a prior art has a problem in that it can cause fatal side effects in women and infants or in males, and can not sustain the effects of hair loss prevention and hair growth with side effects such as acceleration of hair loss due to dermatitis.
  • the present invention solves the above problems, and the object of the present invention is derived from the necessity of the above object is to promote the production and growth of hair through the regeneration and differentiation of hair follicle cells, the inhibition of hair follicle cell death factor, androgen hair loss inhibition And it is to provide a composition that can implement blood circulation improvement and nutritional factors supply.
  • the present invention provides a hair regrowth cosmetic composition having a stable fibroblast growth factor-9 variant (Stable Fibroblast Growth Factor, FGF-9) [Korea Patent Application No. 10-2016-0022666] as an active ingredient. to provide.
  • a stable fibroblast growth factor-9 variant Stable Fibroblast Growth Factor, FGF-9 [Korea Patent Application No. 10-2016-0022666] as an active ingredient.
  • the stabilized basic fibroblast growth factor (stable basic Fibroblast Growth Factor, stable bFGF) [Korean Patent Application No. 10-2015-0078930, PCT patent appl. KR2015 / 07734], Insulin-like Growth Factor (IGF-1), Vascular Endothelial Growth Factor (VEGF), Keratinocyte Growth Factor (KGF-) 2), Stem cell growth factor (Stem Cell Factor, SCF), and noggin peptides (Korean Patent Application No. 10-2013-0114644) preferably further comprises a growth factor complex, but is not limited thereto.
  • a growth factor complex but is not limited thereto.
  • the highly stable fibroblast growth factor-9 variant is preferably the variant described in Korean Patent Application No. 10-2016-0022666,
  • the 117th glycine of SEQ ID NO: 1 is substituted with cysteine, and phenylalanine No. 184 of SEQ ID NO: 1 is a variant substituted with tyrosine, but is not limited thereto.
  • the stabilized basic fibroblast growth factor variant is the 69th and 87th cysteine of SEQ ID NO: 2 is substituted with serine, the 75th alanine is substituted with cysteine, the 50th histidine is tyrosine Substituted [Korean Patent Application No. 10-2015-0078930, PCT patent appl. KR2015 / 007734] is preferred, but is not limited thereto.
  • the sequence of the nogin peptide is preferably a sequence described in Korean Patent Application No. 10-2013-0114644, but is not limited thereto.
  • the composition comprises 0.010 to 5.114 parts by weight of growth factor complex, Superoxide Dismutase (SOD) 0.004 to 0.949 parts by weight based on 70 parts by weight of lyophilized powder, ,
  • SOD Superoxide Dismutase
  • the growth factor complex is 100 to 625 parts by weight of the high stability fibroblast growth factor-9 variant, 100 to 625 parts by weight of the stabilized basic fibroblast growth factor variant, and vascular endothelial cell growth based on 100 parts by weight of insulin-like growth factor-1.
  • Factor 100 ⁇ 625 parts by weight, keratinocyte growth factor-2 100 ⁇ 625 parts by weight, stem cell growth factor 100 ⁇ 625 parts by weight, nogin peptide 100 to 3,200 parts by weight is preferably included, but is not limited thereto.
  • the composition is rice (Oryza Sativa), green tea (Camellia sinensis leaf), black beans (Soybean), licorice (Licorice), Shou (Polygonum multiflorum root), Thuja occidentalis leaf, Grape seed (Grape seed), and ginseng (Panax ginseng root)
  • the extract is 0.05 to 15% by weight of rice, 0.05 to 15% by weight of green tea, 0.05 to 15% by weight of black beans, Licorice 0.002 to 5% by weight, sewage 0.002 to 5% by weight, white leaf 0.002 to 5% by weight, grape seed 0.002 to 5% by weight, ginseng 0.002 to 5% by weight is not limited thereto.
  • the present invention provides a cosmetic composition for improving hair growth comprising the growth factor, high stability fibroblast growth factor-9 variant, high stability basic fibroblast growth factor variant and nogin peptide as active ingredients. .
  • composition of the present invention is very effective for inhibiting hair loss and improving hair growth.
  • the composition of the present invention is used for preventing skin aging, preventing hair loss or promoting hair growth.
  • cosmetic effective amount means an amount sufficient to achieve the skin improving efficacy of the composition of the present invention described above.
  • Cosmetic compositions of the invention may be prepared in any formulation conventionally prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing , Oils, powder foundations, emulsion foundations, wax foundations and sprays may be formulated into, but not limited to. More specifically, it may be prepared in the form of a flexible lotion, nutrition lotion, nutrition cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.
  • the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component.
  • lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular in the case of a spray, additionally chlorofluorohydrocarbon, propane Propellant such as butane or dimethyl ether.
  • a solvent, solubilizer or emulsifier is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
  • liquid carrier diluents such as water, ethanol or propylene glycol
  • suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Castle cellulose, aluminum metahydroxy, bentonite, agar and the like can be used.
  • the carrier component is an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, an isethionate, an imidazolinium derivative, a methyltaurate, a sarcosinate, a fatty acid amide.
  • Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
  • the components included in the cosmetic composition of the present invention include components conventionally used in cosmetic compositions, in addition to growth factors and carrier components as active ingredients, and include, for example, conventional agents such as antioxidants, stabilizers, solubilizers, vitamins, pigments and perfumes. Adjuvants may be included.
  • compositions of the present invention include the growth factor of the present invention, the highly stable fibroblast growth factor-9 variant, the highly stable basic fibroblast growth factor variant, and nogin peptide as an active ingredient, the common contents between the two are The description is omitted to avoid excessive complexity of the specification.
  • the cosmetic composition applied to the present example contains 0.010 to 5.114 parts by weight of growth factor complex and 0.004 to 0.949 parts by weight of superoxide dismutase, based on 70 parts by weight of lyophilized powder.
  • the hair growth factor complex of the present embodiment is composed of high-stable fibroblast growth factor-9, stabilized basic fibroblast growth factor, insulin-like growth factor-1, vascular endothelial growth factor, keratinocyte growth factor-2, and stem cell growth. It consists of factor, nogin peptides.
  • Fibroblast growth factor-9 plays an important role in the regulation of embryonic formation, cell proliferation, cell differentiation and cell migration. It is involved in development, angiogenesis, wound healing and new hair follicle cells, tissue regeneration. Fibroblast growth factor-9 produced in gamma-delta-T cells in the dermis promotes cellular regeneration by promoting intracellular Wnt / beta-catenin signal production. It also regulates the expression of Vascular Endothelial Growth Factor-alpha in lung hepatic tissue.
  • Basic fibroblast growth factor promotes the biosynthesis of collagen and elastin in the dermal layer, promotes angiogenesis of skin cells, enhances skin nutrition and elasticity, promotes hair and skin cell growth, and activates dermal papilla cells.
  • insulin-like growth factor-1 works with insulin-like growth factor-1 to increase hyaluronic acid synthesis in keratinocytes and increase the synthesis of elastin and collagen to regulate the hair cycle to maintain hair condition and prevent hair loss.
  • Insulin-like growth factor-1 is involved in tissue formation such as bones, muscles, and nerves, which acts as a growth hormone, helps to produce new blood vessels, improves cell regeneration, and promotes growth of keratinocytes and regulates hair follicle growth.
  • Vascular endothelial growth factor increases plasma protein permeation of capillaries, promotes cell division and migration, promotes renal blood vessel formation, participates in blood vessel maintenance, and increases capillary size and distribution of hair follicles by increasing capillary size and distribution. Increase and promote hair growth.
  • Keratin cell growth factor-2 is involved in the growth and differentiation of keratinocytes, promotes endothelial cells and new hair development, and protects keratinocytes from chemotherapy or UV light to prevent cell damage and hair loss. In the early stages of hair growth, it plays an important role in crosslinking between cell generations.
  • Stem cell growth factors regulate stem and progenitor cell differentiation, regulate the growth and growth of melanocytes, and promote hair growth by regulating hair growth.
  • Noggin peptide is an antagonist of BMP2 (Bone Morphogenetic Protein), which is activated by DHT to inhibit hair loss by inhibiting BMP2, which produces hair follicle cell death factor, and prevents hair loss, promotes hair cell differentiation and hair progenitor cell proliferation. Induces growth.
  • BMP2 Bis Morphogenetic Protein
  • Nogin peptides, analogs of Noggin are specified in the applicant's patent (10-2013-0114644) and, as described in that patent, have demonstrated inhibitory activity against BMP2.
  • Example 1 of the present invention the BMP2 activity of nogin and nogin peptides was controlled even at the minimum concentration of 0.01 mg / ml. The result was shown to decrease by less than 50% (Fig. 1).
  • Example 2 of the present invention in the skin permeability test of the noggin and the noggin peptide, the large noggin can be seen that the skin permeability is about 45% lower than that of the small noggin peptide (Fig. ).
  • Superoxide dismutase is the most potent antioxidant and inhibits the harmful effects of free radicals and prevents cell damage.It also promotes hair follicle protection and hair growth by removing excess oxides produced by excessive DHT immune cell stimulation. do.
  • the basic fibroblast growth factor of the present invention is a highly stable basic fibroblast growth factor variant developed by the applicant of the present application [Korean Patent Application No. 10-2015-0078930], which is a thermodynamic instability which is a problem of the conventionally distributed basic fibroblast growth factor and Basic fibroblast growth factor variants that overcome short half-lives were used.
  • the basic fibroblast growth factor variants stabilized as a result of comparing the activity according to the incubation test for 24 hours at 37 °C.
  • the natural basic fibroblast growth factor used in the present invention shows excellent stability and activity.
  • the experimental results show that it is necessary to use stabilized basic fibroblast growth factor in place of the existing natural basic fibroblast growth factor in the use of cosmetic materials (FIG. 3).
  • Fibroblast growth factor-9 of the present invention is a high stability fibroblast-9 growth factor variant developed by the applicant of the present application [Korean Patent Application No. 10-2016-0022666], and thermodynamic instability that is a problem of the conventional fibroblast growth factor-9 and The high stability fibroblast growth factor-9 variant was used to overcome the short half-life.
  • the high-stable fibroblast growth factor-9 mutant was It shows superior stability and activity compared to the native fibroblast growth factor-9 used in the present invention.
  • the activity of the native fibroblast growth factor-9 was confirmed to show only 15% of the activity.
  • the experimental results show that it is necessary to use high-stable fibroblast growth factor-9 in place of the existing natural fibroblast growth factor-9 in the use of cosmetic materials (FIG. 4).
  • the growth factor complex of the present invention is 100 ⁇ 625 parts by weight of the high stability fibroblast growth factor-9 variant, 100 ⁇ 625 parts by weight of the stabilized basic fibroblast growth factor variant, vascular endothelial with respect to 100 parts by weight of insulin-like growth factor-1 100 to 625 parts by weight of cell growth factor, 100 to 625 parts by weight of keratinocyte growth factor-2, 100 to 625 parts by weight of stem cell growth factor, and 100 to 3,200 parts by weight of nogin peptides.
  • the hair care composition containing the growth factor complex and superoxide dismutase has a composition as shown in Table 1 below. This composition is the same as the composition used in the prior patent [Korean Patent Application No. 10-2015-0099764] and is attached below Table 1.
  • Table 1 shows the components and contents of the haircare composition.
  • the excipient mannitol is a product of JUNSEI company, and the hair nutrient and conditioning agent, and all other ingredients used are products of SIGMA-ALDRICH company.
  • Growth factor complexes and antioxidants were produced by PNP Biofarm Co., Ltd. and added to the composition, all of the other growth factors are commercially available, but the high stability fibroblast growth factor-9 variant is SEQ ID NO.
  • the stabilized basic fibroblast growth factor variant of the 117th glycine of SEQ ID NO: 1 is substituted with cysteine, the phenylalanine of No.
  • the growth factor produced by PNP Biofarm is a recombinant human growth factor produced by E. coli .
  • Hair care composition applied to the present embodiment is characterized in that it comprises one or more of purified water, buffer or rice, green tea, black beans, licorice, sewage, ephedra, grape seed, and ginseng extract.
  • Rice extract contains high quality dietary fiber and vitamins, functional glycosides and unsaturated fatty acids oleic acid and linolenic acid, which help skin sedation and aging skin care.
  • Green tea extract is effective in preventing pigmentation and preventing skin convergence, such as catechins, which inhibit free radicals and contain a lot of polyphenols.
  • Black soybean extract keeps the scalp transparent and shiny by nourishing the skin with excellent antioxidant and rejuvenating effects. Excellent skin soothing effect prevents various troubles.
  • Licorice extract smoothes skin and has antibacterial properties. It has less side effects on the skin and prevents aging with cell regeneration effect.
  • Sewage extract regulates skin immunity and provides elasticity and energy to skin that is tired from aging, helping to manage vital skin. It nourishes your hair to help you keep it healthy.
  • the leaf extract has antibacterial and antiseptic effects. It is helpful for oily scalp, itching and dandruff, and it is effective in preventing hair loss.
  • Grape seed extract contains proanthocyanidins, which prolong hair growth and promote hair epithelial cell growth. In addition, it inhibits TGF-beta1 and TGF-beta2, which are representative hair loss inducing factors, to inhibit the degenerative phase induction of hair caused by differentiation and cell death of keratinocytes.
  • Ginseng extract promotes blood circulation and metabolism, creating a scalp environment and helping hair grow. Saponin contained in ginseng extract is effective in preventing inflammation of the pores and sebum of the scalp.
  • the extract of the present invention is rice 0.05 ⁇ 15% by weight, green tea 0.05 ⁇ 15% by weight, black beans 0.05 ⁇ 15% by weight, licorice 0.002 ⁇ 5% by weight, sewage 0.002 ⁇ 5% by weight, white leaf 0.002 ⁇ 5% by weight, grape seed 0.002 to 5% by weight, ginseng 0.002 to 5% by weight.
  • the base of the hair care composition can be used as long as it is commonly used, for example, purified water, butylene glycol, 1,2-hexanediol, glyoxal, modified alcohol, glycerin, sodium hyaluronate, hydride Hydroxyethyl cellulose, allantoin.
  • examples of other ingredients formulated in the present compositions include, but are not limited to, stabilizers, preservatives, thickeners, skin moisturizers, hair nutrients, and the like.
  • the hair care composition may include components that may serve to supply nutrients to hair follicles or hair growth promoting auxiliary components that are commonly used.
  • the hair care composition may include vitamins, amino acids, sodium chloride, and the like.
  • the vitamins are characterized by containing one or more selected from the group consisting of vitamin B group, choline, inositol, ascorbic acid, vitamin A, D, E, K.
  • the cosmetic composition containing a growth factor complex comprising the growth factor and the stable fibroblast growth factor-9 variant of the present invention, a stabilized fibroblast growth factor variant and a noggin peptide may be used for the regeneration and growth of hair follicle cells. It is effective in promoting hair growth and preventing hair loss.
  • Figure 2 is a result showing the skin permeability of nogin and nogin peptides over time.
  • Figure 3 is a comparison of the stability of the stabilized basic fibroblast growth factor variant of the present invention and the 37 ° C preservation experiment of the native basic fibroblast growth factor.
  • Figure 4 is a comparison of the stability of the high stability fibroblast growth factor-9 variant of the present invention and the native fibroblast growth factor-9 in 37 °C preservation experiment.
  • FIG. 5 is a table of hair care compositions categorized according to the type of hair loss of the patient group recruited for treatment with MTS.
  • FIG. 7 is a table classifying the recruited patient group for hair care cosmetic material composition according to the type of hair loss.
  • FIG. 8 is a diagram showing the effect of the hair care cosmetic material composition on the entire patient.
  • FIG. 9 is a table of patient groups recruited for comparison experiments with prior hair care compositions [Korean Patent Application No. 10-2015-0099764] according to the type of hair loss.
  • FIG. 10 is a chart showing the effect of a haircare cosmetic material composition on all patients recruited for comparative experiments with the preceding haircare composition.
  • composition of the alkaline phosphatase buffer solution was 100 mM glycine (Junsei, Cat No. 27185-0350), 1 mM MgCl 2 (Kanto, Cat No. 25009-01), 0.5% Triton X-100 (pH 8.8). Large Purification Gold, Cat No.8566-4400).
  • cryopreservation solution of C2C12 (ATCC no. CRL1772) cells to 10 mL of cell culture and mix well. After centrifugation at 800 rpm for 10 minutes, the supernatant is completely removed, and 10 mL of the cell culture solution is added again and mixed well. This was added to a T175 flask and 20 mL of the cell culture solution was added, followed by incubation for 48 hours in a 37 ° C. carbon dioxide incubator (ASTEC, Cat No. SCI-165D). Remove the culture from the T175 flask, wash once with 10 mL PBS, and add 5 mL trypsin-EDTA.
  • BMP2 and nogin and nogin peptides were added to 20 mg acetic acid so that each concentration was 1 mg / ml.
  • BMP2 and nogin and nogin peptides were mixed in 4 mL of DMEM medium according to the seven concentration conditions, and reacted in advance for 1 hour. After removing all cultures incubated for 12 hours in a 24-well plate, the medium in which BMP2 and peptide were reacted was placed in each groove and reacted in a 37 ° C. carbon dioxide incubator for 3 days. After removing the culture medium from the 24-well plate treated with the material for 3 days, add 300 ul of alkaline phosphatase reaction solution to each groove and react for 30 minutes at room temperature.
  • Table 2 shows the concentrations of BMP2, nogin and nogin peptides treated in DMEM medium.
  • Neoderm E (TegoScience) and PBS (Sigma, Cat No. P-5368) are prepared for this experiment. Put the magnetic stirring rod in the Franz cell and add 5 ml PBS. Raise the stratum corneum of Neoderm E upwards on the Franz cell. Lift the Franz cell lid on top of the Neoderm E, secure it completely with the clamp, and then place the Franz cell in the Franz cell service system. 500 ⁇ l of the nogin and nogin peptides in 0.1 mg / ml sample on Neoderm E were then sealed with parafilm and operated at 600 rpm. According to the experimental design, 150 ul of samples to be analyzed at each time using a syringe are analyzed by HPLC (High Performance liquid Chromatography) (FIG. 2).
  • HPLC High Performance liquid Chromatography
  • Example 3 Analysis of Activity Comparison of Basic Fibroblast Growth Factor with Increased Stability and Stability with Time at 37 °C
  • the experiment using the cell proliferation capacity was carried out.
  • the NIH-3T3 cells used in the experiments were maintained using DMEM complete medium containing 10% heat-inactivated fetal bovine serum, 100 units / ml penicillin, and 100 mg / ml streptomycin. 2x10 3 cells / well of NIH-3T3 cells were dispensed on a 96 well culture plate. NIH-3T3 cells incubated for 24 hours were treated with serum-free DMEM medium after starvation in DMEM medium containing 0.5% FBS for each concentration and incubated for 12 hours.
  • MTT [3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyl-2H-tetrazolium bromide] solution was added and reacted for 2 hours, followed by a formazan crystal with 100 ul of DMSO. Was dissolved. Absorbance was measured at 540 nm using a spectrophotometer. Susceptibility to drugs was compared as a percentage in drug treatment wells for absorbance of untreated drugs (control) (FIG. 3).
  • Example 4 Activity Comparison Analysis of Natural and High Stability Fibroblast Growth Factor-9 with Time at 37 ° C
  • BALB-3T3 cells used in the experiment were maintained using DMEM complete medium containing 10% heat-treated inactivated fetal bovine serum, 100 units / ml penicillin, and 100 mg / ml streptomycin. 2x10 3 cells / well BALB-3T3 cells were dispensed into 96 well culture plates. BALB-3T3 cells incubated for 24 hours were treated with serum-free DMEM medium in DMEM medium containing 0.5% FBS at different concentrations, and then cultured for 12 hours.
  • MTT [3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyl-2H-tetrazolium bromide] solution was added and reacted for 2 hours, followed by a formazan crystal with 100 ul of DMSO. Was dissolved. Absorbance was measured at 540 nm using a spectrophotometer. Susceptibility to drugs was compared as a percentage in drug treatment wells for absorbance of untreated drug (control) (FIG. 4).
  • MTS Mesotrachlorosarcoma
  • Table 1 dissolved in 5 ml purified water
  • MTS Mesothelial Treatment System
  • MTS is a non-surgical skin regeneration procedure using microneedles to induce natural skin wound healing after artificial wounds.
  • the hair care composition was divided into control groups using saline on the right side, and MTS was applied to both sides.
  • Example 6 Example test for hair loss treatment and prevention of hair care cosmetic effect of the test material composition
  • the treatment was progressed for 3 months, and the hair care cosmetic material composition shown in Table 1 was used once daily.
  • the cosmetics dissolved in the freeze-dried powder in 15 ml hair base was used around 0.5-1 ml depending on the progress.
  • the hair care cosmetic composition was divided into control groups using saline on the right.
  • Example 7 Comparative test of hair loss treatment and prevention effect of the hair care composition to which the preceding hair care composition [Korean Patent Application No. 10-2015- 0099764] and high stability fibroblast growth factor-9 added
  • the prior hair care composition [Korean Patent Application No. 10-2015-0099764] was used once daily.
  • the cosmetics dissolved in the freeze-dried powder in 15 ml hair base was used around 0.5-1 ml depending on the progress.
  • the preceding hair care composition was divided into control groups using saline on the right side.
  • the effects of the hair care composition containing the preceding hair care composition [Korean Patent Application No. 10-2015-0099764] and high stability fibroblast growth factor-9 were compared.
  • the previous hair care composition experiment was conducted in the same manner as the existing patent [Korean Patent Application No. 10-2015-0099764] and there were differences depending on the environmental factors and the variation of the population of each experimental group, but there is no problem in determining the tendency.
  • the density and thickness of the hair were increased by 3.7% and 0.5% in the hair care composition containing high stability fibroblast growth factor-9. Therefore, the hair care cosmetics of this embodiment through the test shows an excellent effect on the prevention and treatment of hair loss (Fig. 11).
  • Table 3 shows the effects of ATS on hair care compositions using MTS
  • Table 4 shows the effects of hair care compositions on AGA patients

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition cosmétique de soin capillaire contenant, en tant que principe actif, un mutant du facteur de croissance des fibroblastes 9 hautement stable stimulant la régénération et la croissance des cellules de follicule pileux, et contenant en outre un mutant de facteur de croissance des fibroblastes basique ayant une stabilité accrue et un peptide de noggine. Plus spécifiquement, la présente invention concerne une composition cosmétique capable de produire, par régénération et différenciation de cellules de follicule pileux, la stimulation de la génération et la croissance des cheveux, l'inhibition de facteurs d'apoptose des cellules de follicule pileux, l'inhibition de la perte de cheveux androgénique, l'amélioration de la circulation du sang et l'approvisionnement en facteurs nutritionnels. La régénération et la croissance des cellules de follicule pileux est stimulée et la perte des cheveux est prévenue au moyen de la composition cosmétique de la présente invention, contenant un complexe de facteur de croissance comprenant un facteur de croissance, un mutant du facteur de croissance des fibroblastes 9 hautement stable, un mutant de facteur de croissance des fibroblastes stabilisé et un peptide de noggine, de façon à stimuler la croissance des cheveux et prévenir la perte des cheveux.
PCT/KR2017/002042 2016-02-26 2017-02-24 Composition cosmétique de soin capillaire contenant un mutant de facteur de croissance des fibroblastes 9 hautement stable en tant que substance active Ceased WO2017146514A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160023453A KR102535575B1 (ko) 2016-02-26 2016-02-26 고안정성 섬유아세포 성장인자-9 변이체를 유효성분으로 포함하는 헤어케어 화장품 조성물
KR10-2016-0023453 2016-02-26

Publications (1)

Publication Number Publication Date
WO2017146514A1 true WO2017146514A1 (fr) 2017-08-31

Family

ID=59685637

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/002042 Ceased WO2017146514A1 (fr) 2016-02-26 2017-02-24 Composition cosmétique de soin capillaire contenant un mutant de facteur de croissance des fibroblastes 9 hautement stable en tant que substance active

Country Status (2)

Country Link
KR (1) KR102535575B1 (fr)
WO (1) WO2017146514A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019090008A1 (fr) * 2017-11-03 2019-05-09 Skinqri, Llc Formulation permettant la pousse des cheveux à multiples facteurs
CN112353819A (zh) * 2020-12-04 2021-02-12 上海复佑医疗科技有限公司 一种促进毛发生长的制剂及其制备方法
CN112891517A (zh) * 2021-01-30 2021-06-04 北京益华生物科技有限公司 促进头皮毛囊再生的细胞因子组合物及其制备方法与应用
CN116370336A (zh) * 2023-04-13 2023-07-04 浙江伊瑟奇医药科技有限公司 一种生发防脱精华液及个人护理品
US12303470B2 (en) 2021-06-03 2025-05-20 Skinqri, Llc Method and composition for selective treatment of androgen receptors

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102346391B1 (ko) * 2020-01-28 2022-01-04 주식회사 라비오 모근 및 모발 강화용 조성물
KR102691028B1 (ko) * 2021-11-15 2024-08-05 (주)피앤피바이오팜 안정성이 증가된 인간 각질세포 성장인자1 변이체 및 이의 용도

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003192541A (ja) * 2001-12-26 2003-07-09 Pola Chem Ind Inc 育毛促進剤及び育毛用の皮膚外用剤
US20040014658A1 (en) * 2000-10-31 2004-01-22 Oren Bogin Active variants of FGF with improved specificity
US20070224150A1 (en) * 2005-03-24 2007-09-27 Yongji Chung Growth factor for hair and skin treatment
KR20110092301A (ko) * 2008-11-12 2011-08-17 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 손상된 모낭의 재생을 촉진하는 섬유모세포 성장 인자-9
KR20150034491A (ko) * 2013-09-26 2015-04-03 (주)피앤피바이오팜 Ｂｍｐ 활성 억제 기능을 갖는 신규 펩타이드 및 그의 용도

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014658A1 (en) * 2000-10-31 2004-01-22 Oren Bogin Active variants of FGF with improved specificity
JP2003192541A (ja) * 2001-12-26 2003-07-09 Pola Chem Ind Inc 育毛促進剤及び育毛用の皮膚外用剤
US20070224150A1 (en) * 2005-03-24 2007-09-27 Yongji Chung Growth factor for hair and skin treatment
KR20110092301A (ko) * 2008-11-12 2011-08-17 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 손상된 모낭의 재생을 촉진하는 섬유모세포 성장 인자-9
KR20150034491A (ko) * 2013-09-26 2015-04-03 (주)피앤피바이오팜 Ｂｍｐ 활성 억제 기능을 갖는 신규 펩타이드 및 그의 용도

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EL SHAFEY, HATEM M. ET AL.: "Microbial Superoxide Dismutase Enzyme as Therapeu- tic Agent and Future Gene Thempy", CURRENT RESEARCH, TECHNOLOGY AND EDUCATION TOPICS IN APPLIED MICROBIOLOGY AND MICROBIAL BIOTECHNOLOGY, 2010, pages 435 - 443, XP055412089 *
GAY, DENISE ET AL.: "Fgf9 from Dermal Gamma Delta T Cells Induces Hair Follicle Neogenesis after Wounding", NATURE MEDICINE, vol. 19, no. 7, 2013, pages 916 - 923, XP055412111 *
LEE, NAM-JI ET AL.: "The Latest Patent Trends in Korea with Related to the Health of Hair", KOR. J. AESTHET. COSMETOL., vol. 12, no. 1, 2014, pages 133 - 138 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019090008A1 (fr) * 2017-11-03 2019-05-09 Skinqri, Llc Formulation permettant la pousse des cheveux à multiples facteurs
CN112353819A (zh) * 2020-12-04 2021-02-12 上海复佑医疗科技有限公司 一种促进毛发生长的制剂及其制备方法
CN112891517A (zh) * 2021-01-30 2021-06-04 北京益华生物科技有限公司 促进头皮毛囊再生的细胞因子组合物及其制备方法与应用
US12303470B2 (en) 2021-06-03 2025-05-20 Skinqri, Llc Method and composition for selective treatment of androgen receptors
CN116370336A (zh) * 2023-04-13 2023-07-04 浙江伊瑟奇医药科技有限公司 一种生发防脱精华液及个人护理品

Also Published As

Publication number Publication date
KR102535575B1 (ko) 2023-05-23
KR20170100938A (ko) 2017-09-05

Similar Documents

Publication Publication Date Title
KR101772574B1 (ko) 모낭 세포의 재생과 성장을 촉진하는 성장인자, 고안정성 섬유아세포 성장인자 변이체 및 노긴 펩타이드를 함유한 헤어케어 화장품 조성물
WO2017146514A1 (fr) Composition cosmétique de soin capillaire contenant un mutant de facteur de croissance des fibroblastes 9 hautement stable en tant que substance active
WO2017123022A1 (fr) Exosome dérivé de cellules souches contenant une quantité importante de facteurs de croissance
WO2013027984A2 (fr) Composition cosmétique contenant un composant de thé vert
WO2019194470A1 (fr) Composition pharmaceutique ou cosmétique de prévention ou de traitement de la chute des cheveux ou de stimulation de la croissance capillaire
US20230363999A1 (en) Composition for treating hair loss or promoting hair growth comprising growth factor
WO2023054817A1 (fr) Peptide ayant une activité anti-âge et son utilisation
WO2023055007A1 (fr) Peptide possédant une activité anti-vieillissement, et son utilisation
WO2023055010A1 (fr) Peptide ayant une activité anti-âge et son utilisation
KR102376630B1 (ko) 세포성장촉진 물질을 유효성분으로 함유하는 탈모 개선 또는 발모 촉진용 화장료 조성물
KR102911998B1 (ko) 흰머리 억제용 조성물 및 이의 용도
US20200129386A1 (en) Composition for skin whitening or wound treatment, containing liquid plasma
WO2021075791A2 (fr) Peptide pour réduire la perte des cheveux et favoriser la pousse des cheveux, et composition cosmétique et composition pharmaceutique le comprenant
WO2021162206A1 (fr) Composition pour la prévention ou le traitement de la perte de cheveux comprenant un milieu de culture de tissu de follicules pileux
WO2024228415A1 (fr) Composition pour prévenir ou traiter la chute des cheveux, ou pour favoriser la pousse des cheveux ou la nutrition des cheveux, comprenant, en tant que principe actif, une matrice extracellulaire décellularisée dérivée de kératinocytes cutanés
WO2021157753A1 (fr) Composition pour prévenir la chute des cheveux et stimuler la repousse des cheveux
WO2024210460A1 (fr) Peptide ayant une activité favorisant la pousse des cheveux ou atténuant la chute des cheveux et son utilisation
KR101190815B1 (ko) 세로토닌을 유효성분으로 포함하는 백반증 치료용 조성물
WO2021251730A1 (fr) Composition comprenant de la regentide-034 et de la regentide-041 pour le soin de la peau ou la réduction des rides
WO2022265150A1 (fr) Milieu de culture riche en exosomes de cellules souches immortalisées et composition fonctionnelle comprenant de la toxine botulique
WO2021251727A1 (fr) Regentide-041 et composition comprenant de la regentide-041 pour atténuer une affection cutanée
WO2020241972A1 (fr) Composition cosmétique comprenant de la substance p pour le blanchiment de la peau
WO2025173928A1 (fr) Composition d'amélioration du cuir chevelu à l'aide de pseudomonas et de micrococcus et procédé de préparation associé
WO2015030422A9 (fr) Composition pour accélérer la restauration des cheveux ou la croissance des cheveux, comprenant du 21-o-angéloylthéasapogénol e3
WO2025244384A1 (fr) Procédé pour améliorer la productivité d'une solution de culture de cellules souches, procédé pour l'activer et composition la comprenant

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17756852

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17756852

Country of ref document: EP

Kind code of ref document: A1